Biogen's (BIIB) Big Moves Signal Future Sale
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/30/2026
- Wall Street ends sharply higher, lifted by soaring Microsoft
- Microsoft surges 8% on strong revenue outlook, maintained capex guidance
- Meta sinks 8% after Q3 revenue forecast misses Wall Street estimates
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- Microsoft rally lifts stocks, 30-year Treasury yield hits 19-year peak
- Crude Inventory Fell 7.2 Million Barrels Last Week - EIA
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- Wall Street closes down sharply after Fed holds rates unchanged
- Wall Street ends sharply higher, lifted by soaring Microsoft
- KBR names its Mission Technology Solutions spinoff Trinzic
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
Biogen (BIIB) Announces 3 Major Changes to Get the Stock Moving Higher - BMO Capital
July 21, 2016 8:44 AM EDTBMO Capital analyst M. Ian Somaiya weighed in on Biogen (NASDAQ: BIIB) noting 3 major change were announced this morning to get the stock moving higher:
1) departure of CEO, George Scangos,
2) major cost cutting initiatives that led to 2016 non-GAAP EPS guidance being raised to $19.70-20.00 from... More
Scangos Retirement May Be Precursor to Big M&A Plans at Biogen (BIIB) - Leerink
July 21, 2016 8:24 AM EDTLeerink Partners analyst Geoffrey Porges weighed in on Biogen (NASDAQ: BIIB) after the company reported earnings, announced a $5bn share buyback as well as the retirement of CEO George Scangos.
"We expect BIIBs stock to be modestly higher following these results, but... More
Biogen (BIIB) Approves $5B Stock Buyback Program
July 21, 2016 7:06 AM EDTBiogen (NASDAQ: BIIB) announced that its Board of Directors authorized a program to repurchase up to $5 billion of the Companys common stock. Biogen currently expects that purchases will be executed over the next three years. This share repurchase program is in addition to the... More
